Building Towards Precision Oncology for Pancreatic Cancer: Real-World Challenges and Opportunities

Overview

Journal Genes (Basel)

Publisher MDPI

Date 2020 Sep 24

PMID 32967105

Citations 8

Authors

Yifan Wang

Anna Lakoma

George Zogopoulos

Affiliations

Soon will be listed here.

Abstract

The advent of next-generation sequencing (NGS) has provided unprecedented insight into the molecular complexity of pancreatic ductal adenocarcinoma (PDAC). This has led to the emergence of biomarker-driven treatment paradigms that challenge empiric treatment approaches. However, the growth of sequencing technologies is outpacing the development of the infrastructure required to implement precision oncology as routine clinical practice. Addressing these logistical barriers is imperative to maximize the clinical impact of molecular profiling initiatives. In this review, we examine the evolution of precision oncology in PDAC, spanning from germline testing for cancer susceptibility genes to multi-omic tumor profiling. Furthermore, we highlight real-world challenges to delivering precision oncology for PDAC, and propose strategies to improve the generation, interpretation, and clinical translation of molecular profiling data.

Citing Articles

Canadian National Pancreas Conference 2023: A Review of Multidisciplinary Engagement in Pancreatic Cancer Care.

Nickerson J, Cyr C, Arseneau R, Lee S, Condon-Oldreive S, Zogopoulos G Curr Oncol. 2024; 31(10):6191-6204.

PMID: 39451765 PMC: 11506161. DOI: 10.3390/curroncol31100461.

[Histopathologic diagnosis of solid and cystic pancreatic lesions with a focus on ductal adenocarcinoma : A vademecum for daily practice].

Esposito I, Yavas A, Haberle L Pathologie (Heidelb). 2024; 45(1):5-18.

PMID: 38191761 DOI: 10.1007/s00292-023-01288-0.

Germline BRCA testing in pancreatic cancer: improving awareness, timing, turnaround, and uptake.

Golan T, Casolino R, Biankin A, Hammel P, Whitaker K, Hall M Ther Adv Med Oncol. 2023; 15:17588359231189127.

PMID: 37720496 PMC: 10504836. DOI: 10.1177/17588359231189127.

Adherence to NCCN Genetic Testing Guidelines in Pancreatic Cancer and Impact on Treatment.

Crowley F, Gandhi S, Rudshteyn M, Sehmbhi M, Cohen D Oncologist. 2023; 28(6):486-493.

PMID: 36933202 PMC: 10243789. DOI: 10.1093/oncolo/oyad044.

Intra-Tumoral CD8+ T-Cell Infiltration and PD-L1 Positivity in Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma.

Golesworthy B, Wang Y, Tanti A, Pacis A, Romero J, Cuggia A Front Oncol. 2022; 12:860767.

PMID: 35547873 PMC: 9082359. DOI: 10.3389/fonc.2022.860767.

References

Helleday T . The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol Oncol. 2011; 5(4):387-93. PMC: 5528309. DOI: 10.1016/j.molonc.2011.07.001. View

Smith A, Bascunana C, Hall A, Salman A, Andrei A, Volenik A . Establishing a clinic-based pancreatic cancer and periampullary tumour research registry in Quebec. Curr Oncol. 2015; 22(2):113-21. PMC: 4399608. DOI: 10.3747/co.22.2300. View

Canon J, Rex K, Saiki A, Mohr C, Cooke K, Bagal D . The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019; 575(7781):217-223. DOI: 10.1038/s41586-019-1694-1. View

Tiriac H, Belleau P, Engle D, Plenker D, Deschenes A, Somerville T . Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Cancer Discov. 2018; 8(9):1112-1129. PMC: 6125219. DOI: 10.1158/2159-8290.CD-18-0349. View

. Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. Cancer Cell. 2017; 32(2):185-203.e13. PMC: 5964983. DOI: 10.1016/j.ccell.2017.07.007. View

Pishvaian M, Blais E, Brody J, Lyons E, DeArbeloa P, Hendifar A . Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial. Lancet Oncol. 2020; 21(4):508-518. PMC: 7453743. DOI: 10.1016/S1470-2045(20)30074-7. View

Oettle H, Neuhaus P, Hochhaus A, Hartmann J, Gellert K, Ridwelski K . Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013; 310(14):1473-81. DOI: 10.1001/jama.2013.279201. View

Lord C, Ashworth A . The DNA damage response and cancer therapy. Nature. 2012; 481(7381):287-94. DOI: 10.1038/nature10760. View

Shabihkhani M, Lucey G, Wei B, Mareninov S, Lou J, Vinters H . The procurement, storage, and quality assurance of frozen blood and tissue biospecimens in pathology, biorepository, and biobank settings. Clin Biochem. 2014; 47(4-5):258-66. PMC: 3982909. DOI: 10.1016/j.clinbiochem.2014.01.002. View

10.

Sie A, van Zelst-Stams W, Spruijt L, Mensenkamp A, Ligtenberg M, Brunner H . More breast cancer patients prefer BRCA-mutation testing without prior face-to-face genetic counseling. Fam Cancer. 2013; 13(2):143-51. DOI: 10.1007/s10689-013-9686-z. View

11.

Torphy R, Wang Z, True-Yasaki A, Volmar K, Rashid N, Yeh B . Stromal Content Is Correlated With Tissue Site, Contrast Retention, and Survival in Pancreatic Adenocarcinoma. JCO Precis Oncol. 2018; 2018. PMC: 6262879. DOI: 10.1200/PO.17.00121. View

12.

Flaherty K, Gray R, Chen A, Li S, Patton D, Hamilton S . The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design. J Natl Cancer Inst. 2020; 112(10):1021-1029. PMC: 7566320. DOI: 10.1093/jnci/djz245. View

13.

Lawler M, Siu L, Rehm H, Chanock S, Alterovitz G, Burn J . All the World's a Stage: Facilitating Discovery Science and Improved Cancer Care through the Global Alliance for Genomics and Health. Cancer Discov. 2015; 5(11):1133-6. DOI: 10.1158/2159-8290.CD-15-0821. View

14.

Blando J, Sharma A, Higa M, Zhao H, Vence L, Yadav S . Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. Proc Natl Acad Sci U S A. 2019; 116(5):1692-1697. PMC: 6358697. DOI: 10.1073/pnas.1811067116. View

15.

Dreyer S, Jamieson N, Cooke S, Valle J, McKay C, Biankin A . PRECISION-Panc: the Next Generation Therapeutic Development Platform for Pancreatic Cancer. Clin Oncol (R Coll Radiol). 2019; 32(1):1-4. DOI: 10.1016/j.clon.2019.07.011. View

16.

Golan T, Stossel C, Atias D, Buzhor E, Halperin S, Cohen K . Recapitulating the clinical scenario of BRCA-associated pancreatic cancer in pre-clinical models. Int J Cancer. 2018; 143(1):179-183. DOI: 10.1002/ijc.31292. View

17.

Patel N, Michelini V, Snell J, Balu S, Hoyle A, Parker J . Enhancing Next-Generation Sequencing-Guided Cancer Care Through Cognitive Computing. Oncologist. 2017; 23(2):179-185. PMC: 5813753. DOI: 10.1634/theoncologist.2017-0170. View

18.

Klein A, Brune K, Petersen G, Goggins M, Tersmette A, Offerhaus G . Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res. 2004; 64(7):2634-8. DOI: 10.1158/0008-5472.can-03-3823. View

19.

Hong S, Kelly D, Griffith M, Omura N, Li A, Li C . Multiple genes are hypermethylated in intraductal papillary mucinous neoplasms of the pancreas. Mod Pathol. 2008; 21(12):1499-507. PMC: 2678809. DOI: 10.1038/modpathol.2008.157. View

20.

Nicolle R, Blum Y, Marisa L, Loncle C, Gayet O, Moutardier V . Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenografts. Cell Rep. 2017; 21(9):2458-2470. PMC: 6082139. DOI: 10.1016/j.celrep.2017.11.003. View